01 Sep , 2023
12:00 AM
19 May , 2023
12:00 AM
16 Mar , 2023
12:00 AM
04 Nov , 2022
12:00 AM
04 Nov , 2022
12:00 AM
Results
View DetailsCALLS | PUTS | |||||||||
Total OI | Chg in Ol | Chg % Ol | LTP | Chg % | Strike Price | Chg % | LTP | Chg % OI | Chg in Ol | Total OI |
No Record Found
sector: Pharmaceuticals
as on 9/25/2023 3:40:04 PM
₹ 47.3 2.05 4.5301 Sep , 2023
12:00 AM
19 May , 2023
12:00 AM
16 Mar , 2023
12:00 AM
04 Nov , 2022
12:00 AM
04 Nov , 2022
12:00 AM
Results
View DetailsA full maintenance contract with a post-warranty cost of Rs 43.22 crore, including GST, is included in the contract.
Resolution Type | Desc. of Resolution | Lias Recommendation |
---|
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
Demat Account
Trading Account
PROMOTER - TOTAL67.47%
Indian: 67.47%
Foreign: 0%
NON-PROMOTER - TOTAL 32.53%
Institutions: 0.00%
Non-Institutions: 32.53%
CUSTODIES - 0.00%
Custodies: 0.00%
No Data Available To Display Chart
No Data Available To Display Chart
No Data Available To Display Chart
No Data Available To Display Chart
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 1,127.35 | 65.13 | 2,69,865.20 | 380.64 | 1.02 | 4,383.34 | 98.98 |
Divis Laboratories Ltd | 3,750.95 | 68.16 | 99,629.03 | 345.00 | 0.80 | 1,730.00 | 478.60 |
Cipla Ltd | 1,164.00 | 34.30 | 93,955.61 | 895.02 | 0.73 | 3,857.73 | 305.19 |
Dr Reddys Laboratories Ltd | 5,457.25 | 24.30 | 91,199.58 | 1,639.40 | 0.73 | 5,420.10 | 1,235.20 |
Torrent Pharmaceuticals Ltd | 1,831.00 | 59.03 | 61,876.29 | 323.00 | 1.20 | 2,078.00 | 190.75 |
JFL Life Sciences Ltd. was incorporated as JFL Life Sciences Private Limited on April 25, 2010 as a Private Limited Company under Companies Act, 1956. Pursuant to a Special Resolution held on February 10, 2022, Company converted from a Private Limited to Public Limited Company and name of the Company was changed to JFL Life Sciences Limited, on March 3, 2022. The Company primarily manufactures and market pharmaceutical products. Its product portfolio consists of Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet and Capsules (general) and Oral Rehydration Solutions (ORS). The Company is engaged in domestic as well as international business. With market presence in PAN India, products of JFL is supplied to 10 developed and developing countries throughout the World. To maintain its competitiveness and to further the cause of health care, it has laid a strong R&D foundation and a FDA approved manufacturing facility near Ahmedabad. It also export products to African countries, Middle Eastern countries and CIS countries, mainly through merchant exporters. For the purpose of identification equipment / machinery / containers are appropriately labelled to identify the stage of process. In case of tablets, the materials are quarantined after granulation, compression, coating and final packing operations for clearance from Q.A. before pursuing the next stage of process. In case of capsule, the materials are quarantined after mixing, filling and final... Read More
Reports by JFL Life Sciences Ltd
Reports by JFL Life Sciences Ltd
No Record Found